dulaglutide
China [CN] Trulicity (trade name: Trulicity), a long-acting GLP-1 analogue developed by Eli Lilly for one /w subcutaneous injection, was approved in the United States in September 2014 for the treatment of type 2 diabetes. Structurally, Duraglutide replaces Ala with Gly at position 8 on the GLP-1 (7-37) chain, Gly at position 22, and Arg at position 36, with an average biological half-life of up to 90 hours. In February 2014, clinical results indicated that the efficacy of duraglutide was not inferior to that of liraglutide, and it was the first macromolecule GLP-1 analogue that was not inferior to liraglutide in terms of efficacy. However, the administration frequency of dulaglutide once /w can significantly improve the compliance of patients and is a new product with great potential to compete with Lira Chemicalbook peptide. GLP analogues include GLP-1 analogues and GLP-2 analogues. GLP-1 analogues are mainly used for type 2 diabetes. Marketed drugs include esenatide, liraglutide, lixisenatide, duraglutide and apirutide. While GLP-2 analogues are used for short bowel syndrome, currently only tidolutide is available on the market. GLP-1 analogues are currently a popular field of polypeptides under research. The length of the peptide chain is basically between 31 and 44 amino acids, and there are no disulfide bonds within the structure.
Click enlarge Image